Following the opening words of the event’s organizers, ILSI and Kenes, the president of Israel Shimon Peres came up to the stage and surveyed the future of Israel, which will be based on advanced technologies and serve as an example to the entire world. In his own words, “Israel should become an international lab.” Amen to that.

Neither did the following opening keynote lecture disappoint. Sanofi-Aventis, the multinational pharmaceutical company and the world’s fourth-largest by prescription sales, has presented its new view of developing new products. The lecturer divided the pharmaceutical market into two distinct sections: the small biotechnology companies, and the large business companies. The first kind is usually headed by innovative and creative scientists whose expertise is thinking outside the box. They have good ideas, but they lack the experience needed to break through in the market. That’s what the big pharma companies do exceptionally well: they have all the experience and knowledge needed to succeed in the market, but they lack the ground-breaking minds that can be found in the smaller companies.

The solution, according to Sanofi-Aventis, lies in collaboration. Well, that didn’t require a genius to figure out. Then again, such a collaboration is not easily brought about. On the one hand, the employees of the large companies view themselves as superior to those from the smaller companies. On the other hand, the scientists in the small companies treat their projects as their own personal babies, and refuse to accept criticism and ideas for change. All the same, Sanofi-Aventis is determined to bring about fruitful collaborations between the Davids and the Goliaths of the world. To that purpose, they have cut down their portfolio by 40%, and rewired all the human resources and money that became available into new projects, with a core of efficient and competent employees who collaborate with a variety of other companies.

The end result: since 2010, sixty percent of the compounds in Sanofi-Aventis’ portfolio are developed via collaborations. Such collaborations can also promote projects that integrate knowledge and expertise from different fields, such as glucose sensors connected directly to an insulin pump, or robotic hands that connect to the nervous system.

Let us all hope that this trend – collaboration in place of a take-over – will become more common, and will bring about the development of novel technologies and products more efficiently and in a shorter amount of time.

As part of the BioMed Conference, a Cardiovascular Technology Workshop will be held on Monday, June 14, 12:00–18:30 at the Dan Panorama Hotel, Tel Aviv

This message is also available online

Cardiovascular Therapy in the 2020s An ILSI-BioMed Workshop Sponsored by As part of the BioMed Conference, a Cardiovascular Technology Workshop will be held on Monday, June 14, 12:00–18:30 at the Dan Panorama Hotel, Tel Aviv.The most acclaimed international speakers will address the field’s most relevant and pressing topics, as seen in the program below: 12:10 -12:20  Dr. Francesco Maisano, Dept. of Cardiovascular & Thoracic Medicine, Istituto Scientifico, San Raffaele, Italy and Panel of Moderators OPENING REMARKS 12:20 -12:40    Dr. Michael J. Mack, Director of Cardiovascular Surgery, Baylor Healthcare System, Director of Research, The Heart Hospital Baylor Plano, USA VALVE DISEASE: UNMET NEEDS AND OPTIONS FOR INNOVATION 12:40 -13:00  Prof. Friedrich Wilhelm Mohr, Herzzentrum Universitaet Leipzig, Germany CORONARY ARTERY DISEASE AND HEART FAILURE: UNMET NEEDS AND INNOVATIONS 13:00 -13:15  COFFEE BREAK 13:15 -13:35  Dr. David L. Brown, President and Chairman of the Medical Staff, Director of Interventional Cardiology, Co-Director Cardiovascular Research & Structural Heart Program, The Heart Hospital, Baylor Plano, USA WHAT’S MISSING FROM AN INTERVENTIONAL CARDIOLOGIST 21ST CENTURY ARMAMENTARIUM? 13:35 -14:10    Dr. Joseph M. Smith, Chief Medical and Science Officer, West Wireless Health Institute, USA THE COMING COLLISIONS IN CARDIOLOGY AND THE OBLIGATION FOR INNOVATION 14:10 -15:10   LUNCH 15:10 -15:45   Dr. Bryant M. Moore, Vice President, Research & Technology, Medtronic, New Therapies & Diagnostics, USA ADVANCES IN ENGINEERING AND SCIENCE AND THE DEVELOPMENT OF FUTURE IMPLANTABLE SYSTEMS 15:45 -16:20  Dr. Assaf Govari, Biosense Webster Ltd., Israel EP LAB OF THE FUTURE 16:20 -16:40  Dr. Guy Ezekiel, CEO, Medtronic Ventor Technologies, Ltd, Israel VENTOR AS A STRATEGIC ACQUISTION TARGET: WHAT CAN BE LEARNED FROM THIS CASE? 16:40 -17:00   Dr. Bruce Kenknight, CEO, Valtechcardio Medical, Israel VALTECH’S BROAD BASE PRODUCT LINE STRATEGY 17:00 -17:20   COFFEE BREAK 17:20 -18:20   COMPANY PRESENTATIONS AND PRIVATE CONSULTATIONS with the experts 18:20 -18:30    CLOSING REMARKS To confirm a time for your presentation and consultation, please contact dikla@valtechcardio.com by Wednesday, June 9, 2010. For conference registration, please contact reg_biomed2010@kenes.com.       IN COOPERATION WITH ORGANIZED BY MEDIA PARTNERS   Conference website: www.kenes.com/biomed Conference Organizers   Kenes International P.O.Box 56, Ben-Gurion Airport 70100, Israel Tel: 972-3-9727500 Fax: 972-3-9727555 E-mail: biomed@kenes.com   SPONSORS   DIAMOND PLATINUM      GOLD                             SILVER         BRONZE

Medical Innovation:

 From Idea to Bench to Bedside

A Biomedical Innovation Summit

Dan Panorama Tel Aviv ¡ Sunday, June 13, 2010

Presented by

Cleveland Clinic

Global Cardiovascular Innovation Center

Israel Life Sciences Industries

And Sponsored By

GT Greenberg Traurih, MPR, PriceWaterhouseCoopers, Team Neo, Cleveland Plus Business

Program

8:45                 Registration, Breakfast, Networking

9:15                 Welcome and Introductions

                        Ruti Alon, Chair ILSI

                        Mark Low, Global Cardiovascular Innovation Center

                        Richard Schottenstein, The Ohio Department of Development

9:30                 How new products are conceived and developed

                        Yossi Gross, Israel most prolific biotech innovator

                        Guy Shinar, Medical Device Entrepreneur

10:30               The Future of Innovation in the US–What is the Market Looking For

                        Laurence Kennedy, MD of Endocrinology, Diabetes, and Metabolism Department, Cleveland Clinic

                       Mark Low, Managing Director, Global Cardiovascular Innovation Center

                        Philip R. Schauer, MD, Chief of Minimally Invasive General Surgery and Director Bariatric and Metabolic Institute Cleveland Clinic

                        Rishi Singh, MD, Department of Ophthalmology, Cleveland Clinic

12:30               Lunch

13:30               KEYNOTE

                        Case Study in Medical Innovation

                        Israeli Companies and the US Market

                        Avshalom Horan, Chairman Simbionix                                                            

                        Avner Halperin, CEO Early Sense

                        Amir Ronen, CEO Sensible Medical Innovation

14:15               Design, Development, Engineering                                            

                        A Proven Process of Product Development                             

                        Christian Haller, MPR, Inc

14:45               From IP to FDA; FROM IDEA TO COMPANY

                        Understanding the legal Landscape

                        Robert Grossman, Partner Greenberg Traurig, LLP.

15:30               The “Business of Innovation”

                        Claudio Yarza, PricewaterhouseCoopers, Israel

16:00               Funding, Funding, Funding: Key throughout the process

                        Ruti Alon, General  Partner Pitango Venture Capital

                        Michael Goldberg, Managing Partner Bridge Investment Fund

                        Mark Low, Global Cardiovascular Innovation Center

                        Dalia Megiddo, Managing Partner 7 health Ventures

                        Richard Schottenstein, The Ohio Department of Development

                        Neil Wyant, FirHill LLC – Venture arm of the Kanfer Family

17:00               Working in North America

                        From Clinical Relationships to Corporate Partnerships

                        Everything you Wanted to Know, but did not Know Whom to Ask

                        Mark Low, Global Cardiovascular Innovation Center

                        Laurence Kennedy, MD, Chairman of Endocrinology, Diabetes, and Metabolism Department, Cleveland Clinic

                        Philip R. Schauer, MD, Chief of Minimally Invasive General Surgery and Director Bariatric and Metabolic Institute Cleveland Clinic

                        Rishi Singh, MD, Department of Ophthalmology, Cleveland Clinic

17:45               WRAP

18:00               NETWORKING RECEPTION

SAVE THE DATE

May 11^th, 16:00-19:00

Beit Chel Ha’avir, 15  Jabotinski Street, Herzelia

Advantages of Manufacturing in Israel

The seminar will focus on issues related to options, advantages and Governmental policies associated with manufacturing of Medical Devices and Biopharma products in Israel. 

The event will be moderated by Moshe Mizrahy, founder of Nitzanim Medical Fund 

Agenda

16:00-16:20           Moshe Mizrahy – Introduction

16:20-16:40           Dr. Ora Dar, Head of Life Sciences Sector & Biotechnology Consultant to the Chief Scientist  
“Chief Scientist policies as related to manufacturing in Israel” 

16:40:17:00           Uri Bechor, Flextronics – electronics, mechanical, optics, 
                                      lasers  

17:00: 17:20          Shmulik Glick, STI Laser – special metal devices 

17:20-17:40          Shuki Weinstein, Sorvan – Sterilization of Medical Devices 

17:40-18:00          Dr. Elisheva Yonish-Rouach, Protein Production Services 
                                     (PPS) – protein production

18:00-18:20          Dr. Shimon Amselem, Nextar Ltd., Aminolab – GMP/GLP 
                                     Pharma manufacturing and formulation facility

18:00-18:20          Nadav Weininger, Cure Medical Neopharm Group – Pharma 
                                     and Medical Device manufacturing facility

18:20-18:40          Q&A, Conclusion

Who Should Attend? 

CEO, COO and CFO of life science start-up companies
Operations managers, purchasing & procurement managers 
QC managers

Participation fees of 100 NIS for non ILSI members and 50 NIS for ILSI members, 
will be collected at the entrance

PLEASERSVP!!! at  03-600-5008 or   03-600-5118
sima@ilsi.org.il ; ayelet@ilsi.org.il
ILSI | 155 Bialik St. | Ramat Gan | | 52523 | Israel | 03-6005008/118

esnr-prospect-10_[1]

Registration_form.FINAL![1]

The following is information on a Course on Medical Patents and IP starting on April 11. Registration closes March 24.

קורס בנושא  ”פטנטים וקניין רוחני במדעי החיים והרפואה”

מבוא: הכרת מערכת הפטנטים והחוקים הבינלאומיים על פיהם היא מתנהלת תקנה למדענים ויזמים במדעי החיים כלים להבנת התעשיה וחשיבותו של הפטנט בהגנה על רעיונות וטכנולוגיות. הבנת מבנה מסמך הפטנט ומטרותיו משפרת את סיכויי המסחור לתועלת הארגון והיזם הבודד. להרשמה, נא להתקשר בהקדם אל מזכירות ביה”ס ללימודי המשך ברפואה, טלפונים:03-6409797,6409228. ההרשמה עד 24 במרץ 2010.פתיחת הקורס מותנית במספר הנרשמים עד לתום מועד ההרשמה.                     - – - – - – - – - – - – - – - – - – - – - – -  תכנית הקורס:

MedChem-poster[1]

שלום לכולם
ביום ג’ 16.3.010 יתקיים הכנס השמיני של הסקציה לכימיה תרופתית.
נא ראו קבצים מצורפים.
הנכם מוזמנים להשתתף בכנס.
בברכה
 
מלכה נחמיה
טל. 02-6758683
פקס: 02-6757076

–
Anitta Harrison
Secretary, Israel Chemical Society
Department of Organic Chemistry
Weizmann Institute of Science
P.O.Box 26, Rehovot 76100

Email:      ics.sec@gmail.com
Website:  http://www.chemistry.org.il
Phone:     08-9343829
Fax:         08-9344142
Mobile:     050-6759491